HONG KONG – Chinese vaccine developer Cansino Biologics Inc. is on its way to becoming the seventh pre-revenue biotech to list in Hong Kong. Expected to debut on the main board of the Hong Kong Stock Exchange (HKEX) on March 28, Cansino aims to raise up to HK$1.26 billion (US$160.5 million).